Facing pressure in diabetes, Novo Nordisk plans next big push – obesity

The world’s largest diabetes drug-maker, Novo Nordisk (NYSE:NVO), is reportedly looking to boost its efforts to treat obesity as the company’s well-established diabetes drugs face competition. At Novo Nordisk’s capital markets day yesterday, CEO Lars Fruergaard Jorgensen told investors that the company wants to rival surgery with their drugs as a solution for obesity. The drug-maker’s first target – semaglutide. Get the full story at our sister site, Drug Delivery Business News. The post Facing pressure in diabetes, Novo Nordisk plans next big push – obesity appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Diabetes Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news